PHASE I/II TRIAL OF CPT-11 AND TEMOZOLOMIDE IN RECURRENT MALIGNANT GLIOMA

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is closed to new enrollment. (Clinical trial summary from the National Cancer Institute's PDQ database) Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. This is a Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma. Patients will receive temozolomide by mouth once a day on Days 1-5 and an infusion of irinotecan on Days 1 and 14. Treatment may be repeated every 4 weeks for up to 1 year. Patients will receive follow-up evaluations every 2 months for 1 year, every 3 months for 1 year, every 4 months for 1 year, and every 4-6 months thereafter.